GT-02216
GT-02216 can bind to GCase allosterically and enhance its activity. GT-02216 enhances the activity of GCase in primary human fibroblasts dose-dependently reduces the accumulation of its substrate, hexosylsphingosine (HexCer) . GT-02216 reduces the Tau accumulation in mutant GBA1 fibroblasts. GT-02216 can be used for the study of Parkinson’s disease[1].
Product Specifications
CAS Number
[2648407-76-3]
UNSPSC
12352005
Target
Glycosidase
Related Pathways
Metabolic Enzyme/Protease
Applications
Neuroscience-Neurodegeneration
Field of Research
Metabolic Disease; Neurological Disease
Purity
98.91
Smiles
O=C(C1=NC(N)=CC(NC2=C(O)C=CC=C2)=C1)N(CC3)CCN3C4=CC=CC=C4
Molecular Formula
C22H23N5O2
Molecular Weight
389.45
References & Citations
WTL444P/L444P
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
MBS1125191-01 0.05 mg (E-Coli)
Recombinant Cryptococcus neoformans var. neoformans serotype D Histone H2B (HTB1)
Ask
View Details MBS1125191-02 0.05 mg (Yeast)
Recombinant Cryptococcus neoformans var. neoformans serotype D Histone H2B (HTB1)
Ask
View Details 
MBS1125191-03 0.2 mg (E-Coli)
Recombinant Cryptococcus neoformans var. neoformans serotype D Histone H2B (HTB1)
Ask
View Details MBS1125191-04 0.5 mg (E-Coli)
Recombinant Cryptococcus neoformans var. neoformans serotype D Histone H2B (HTB1)
Ask
View Details